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Summary (word count: 228) 
SLC12A3 encodes the thiazide-sensitive sodium chloride cotransporter (NCC), which is 
primarily expressed in the kidney, but also in intestine and bone. In the kidney, NCC is located in 
the apical plasma membrane of epithelial cells in the distal convoluted tubule. Although NCC 
reabsorbs only 5 to 10% of filtered sodium, it is important for the fine-tuning of renal sodium 
excretion in response to various hormonal and non-hormonal stimuli. Several new roles for NCC 
in the regulation of sodium, potassium, and blood pressure have been unraveled recently. For 
example, the recent discoveries that NCC is activated by angiotensin II but inhibited by dietary 
potassium sheds light on how the kidney handles sodium during hypovolemia (high angiotensin 
II) and hyperkalemia. The additive effect of angiotensin II and aldosterone maximizes sodium 
reabsorption during hypovolemia, whereas the inhibitory effect of potassium on NCC increases 
delivery of sodium to the potassium-secreting portion of the nephron. In addition, great steps 
have been made in unraveling the molecular machinery that controls NCC. This complex 
network consists of kinases and ubiquitinases, including WNKs, SGK1, SPAK, Nedd4-2, Cullin-
3 and Kelch-like 3. The pathophysiological significance of this network is illustrated by the fact 
that modification of each individual protein in the network changes NCC activity and results in 
salt-dependent hypotension or hypertension. This review aims to summarize these new insights 
in an integrated manner while identifying unanswered questions.  
 
Keywords: Aldosterone; Angiotensin II; Hypertension; Tacrolimus; Thiazide; WNK kinase.  
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Typical hallmarks of NCC 
The presence of a sodium chloride cotransporter was first suggested in urinary bladder of the 
winter flounder [95, 96]. Subsequent studies in this tissue demonstrated that this cotransporter 
could be inhibited by thiazide diuretics [111] and the cDNA encoding this transporter was 
isolated [31].  
Studies using micropuncture and isolated perfused tubules had identified the same 
pharmacological and kinetic transport characteristics in the early distal convoluted tubule (DCT) 
of rat kidney [23, 60]. Indeed, Gamba and colleagues succeeded in isolating cDNA of the sodium 
chloride cotransporter from rat kidney [30]. NCC is encoded by the SLC12A3 gene (55-kb, 26 
exons) and belongs to the SLC12 family of electroneutral cation chloride cotransporters [29]. 
Besides the kidney, NCC was shown to be expressed in intestine and bone where it is likely 
involved in sodium and calcium absorption [4, 20]. It has been suggested that NCC is expressed 
in various other tissues but this has not been confirmed [29]. In the kidney, NCC is located in the 
early part of the DCT (also called DCT1) (Figure 1), but gradually decreases along the later 
part of the DCT (DCT2), where it co-localizes with the epithelial sodium channel (ENaC) [3]. 
The sodium chloride cotransporter (NCC) mediates the reabsorption of sodium across the apical 
membrane of the DCT (Figure 1) [23]. Chronic activation or inhibition of NCC is usually 
accompanied by morphological changes in the DCT resulting in hypertrophy or atrophy [21, 61, 
66, 126]. The gradient required for sodium chloride transport through NCC is generated and 
maintained by the basolateral sodium-potassium ATPase pump. The potassium that enters the 
cell via this pump is recycled by basolateral potassium transporters. In addition, potassium 
may also be secreted apically by the renal outer medullary potassium channel (ROMK) and a 
potassium chloride cotransporter [133]. In addition, NCC modulates transcellular magnesium 
and calcium reabsorption in the DCT through interaction with the transporters TRPM6 and 
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TRVP5, respectively (Figure 1) [16, 85]. Only 5 to 10% of the filtered load of sodium is 
reabsorbed in the DCT and this is primarily mediated by NCC [23]. Despite this modest 
contribution to overall sodium reabsorption, the NCC in the DCT together with ENaC in the 
connecting tubule (CNT) and the collecting duct (CD) fine-tunes the final concentration of 
sodium chloride in the urine. This is possible because it is not affected by the tubuloglomerular 
feedback [29]. Due to this property, NCC plays a pivotal role in extracellular fluid volume and 
blood pressure control [29].  
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Structure–function relationship  
 
In humans, NCC is a membrane glycoprotein of 1,021-amino acid residues which resembles the 
general topology of the sodium-potassium-chloride cotransporters 1 and 2 (NKCC 1 and 2) [70]. 
NCC is able to form dimers, and it is likely that it functions as a dimer [18, 29]. It consists of 12 
putative transmembrane (TM) spanning regions with a central hydrophobic domain (Figure 2). 
Between TM7 and TM8 there is a large extracellular hydrophilic loop that contains two 
glycosylation sites (N404 and N424) [50]. These glycosylation sites are essential for functioning 
and surface expression of NCC [40]. When glycosylation is eliminated, thiazide diuretics have 
much greater access to their binding sites, which suggests that glycosylation blocks the affinity 
for thiazides [50]. A study that interchanged the transmembrane regions between rat and flounder 
NCC revealed that affinity-modifying residues for chloride are located within the TM1-7 region 
[78]. Especially, a highly conserved glycine within TM4 plays a crucial role for the affinity of 
chloride [78]. The TM8-12 region, distal to the extracellular loop, is sensitive to thiazides. 
Site-directed mutagenesis was used to show that a single residue in TM11 defines the different 
affinity for thiazides between mammalian and flounder NCC [12]. Both transmembrane 
regions appear to have affinity for extracellular sodium. The central domain is flanked by a short 
amino-terminal domain (N-terminus) and a long carboxy-terminal domain (C-terminus) which 
are both located intracellularly (Figure 2) [29]. The N-terminus of NCC contains several 
conserved phosphorylation sites including threonine 46, 55 and 60 and serine 73 and 91 in 
humans [19]. In rats and mice these phosphorylation sites correspond to threonine 44, 53, 58 and 
serine 71, 89, and 124. Phosphorylation of NCC appears to determine its activity, especially at 
threonine 60 in humans or 58 in rat. Indeed, a mutation in threonine 60 is a common cause of 
Gitelman syndrome [65], the disorder resulting from NCC inactivation (see further). The 
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development of a knock-in mouse model with this mutation exhibits the Gitelman phenotype and 
did so because mutant NCC was restricted to the cytosol [138]. Because phosphorylated NCC 
has thus far only been found in the apical plasma membrane of the DCT, anchoring in the plasma 
membrane seems necessary for phosphorylation to occur [91]. This suggests that, apart from 
phosphorylation, the trafficking of NCC from subapical vesicles to the plasma membrane is also 
important [42].  
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Physiological functions  
NCC is highly regulated by hormones, including aldosterone, angiotensin II, glucocorticoids, 
estrogen, insulin, norepinephrine, and vasopressin (Table 1) [13, 53, 82, 83, 91, 108, 118, 124, 
125]. The fact that NCC is regulated by so many different hormones suggests that sodium 
reabsorption through NCC is an important homeostatic control mechanism. Aldosterone was the 
first hormone recognized to be capable of activating NCC [53] and the DCT is therefore part of 
what has been called the “aldosterone-sensitive distal nephron” (ASDN) [77], which was defined 
to comprise the DCT2, the CNT and the CD [67]. Experimentally, aldosterone upregulates NCC 
both when it is directly infused or when it is secreted in response to a low sodium diet [14, 53]. 
The acute effect of aldosterone only involves phosphorylation of NCC [56], whereas the chronic 
effect also increases the total protein abundance of NCC [53], which likely occurs independent 
from changes to NCC mRNA levels [1, 69, 119]. The regulation of NCC by aldosterone seems 
logical, because at least the endportion of the DCT expresses the enzyme 11-beta-hydroxysteroid 
dehydrogenase II which rapidly inactivates glucocorticoids and hence provides 
mineralocorticoid-sensitivity to the epithelial cells [6]. The discovery that angiotensin II is also 
capable of activating NCC was more surprising, because its actions were believed to be confined 
to the proximal tubule [75]. By adrenalectomizing rats and selectively re-infusing aldosterone or 
angiotensin II, we were able to dissect the stimulatory effects of angiotensin II and aldosterone 
on NCC [118]. In a subsequent study we showed that aldosterone did not require angiotensin II 
for activation of NCC, although the presence of both stimuli led to an additive response [119]. 
This additive response may be useful to maximize sodium reabsorption during hypovolemia, 
because this is characterized by elevated plasma levels of both angiotensin II and aldosterone 
[122]. Increased sodium reabsorption in the DCT by NCC will also decrease the delivery of 
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sodium to the CNT and CD [42]. Because in these segments sodium reabsorption is 
electrochemically coupled to potassium secretion, decreased delivery of sodium will help 
conserve potassium. In line with this, recent studies have shown that angiotensin II directly 
inhibits ROMK, further contributing to potassium conservation during hypovolemia [49, 129, 
140]. The effects of angiotensin II on NCC and ROMK therefore help to understand the 
aldosterone paradox, the question how aldosterone increases sodium reabsorption during 
hypovolemia, but potassium secretion during hyperkalemia [3, 122]. Further insight into the 
aldosterone paradox comes from the effects of potassium on NCC. Recent studies have shown 
that dietary potassium inhibits NCC [110, 121]. Gastric gavage of potassium in mice increased 
both urinary potassium and sodium excretion [110]. This response occurred within minutes and 
was independent from aldosterone, because it could also be induced in aldosterone-deficient 
animals. In the kidney, this was accompanied by dephosphorylation of NCC (Figure 4A). The 
increased delivery of sodium to the more distal nephron parts facilitates sodium–potassium 
exchange and therefore kaliuresis. This “potassium-induced natriuresis” appears to constitute an 
important physiological response. Namely, potassium-induced natriuresis could still be evoked 
when a high potassium diet was combined with a low sodium diet [121]. This was accompanied 
by a reduced abundance of total NCC; phosphorylated NCC was also reduced, although this 
did not reach statistical significance (Figure 4B). Taken together, these and other recent 
results seem to suggest that when the organism is faced with the choice between conserving 
sodium or secreting potassium, it chooses the latter [27]. The focus of future research will be to 
identify the signal by which dietary potassium induces NCC downregulation. Similar to high 
dietary potassium, high dietary sodium also suppresses NCC [14]. This response, however, is not 
as rapid as the one for high potassium diet [110] and involves a decrease in the plasma 
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membrane abundance of sodium transporters all along the nephron [28, 137]. Furthermore, the 
effect of high dietary sodium on NCC appears to be mediated through aldosterone [14], 
although the effect of high dietary sodium on NCC has not been studies in the absence of 
aldosterone. Similarly, chronic metabolic acidosis also increases aldosterone and therefore NCC 
[26]. Why other hormones such as insulin [13, 57, 108, 109], vasopressin [83, 91, 104], estrogen 
[125], and norepinephrine [82] regulate NCC is less clearly defined (Table 1), but warrants 
further study given the role of these hormones in normal physiology and human diseases such as 
diabetes mellitus, obesity, and hypertension.   
 
The NCC signaling cascade  
Kinases 
The intracellular signaling cascade that controls NCC activity has largely been unraveled in 
recent years (Figure 3). This NCC signaling cascade consists of a multikinase network which 
includes the kinases WNK, SPAK, OSR1, and SGK1 [130]. More recently, proteins involved in 
ubiquitylation including Nedd4-2, Kelch-like 3, and Cullin 3 were also found to regulate NCC 
[2, 7, 68, 99]. Many of these regulatory proteins were identified because mutations in their genes 
result in familial hyperkalemic hypertension (FHHt, also called pseudohypoaldosteronism type II 
or Gordon syndrome, see also “Relation to diseases” below). WNKs appear to modulate both 
the “trafficking” and phosphorylation of NCC [41], although most of our knowledge has been 
derived from studies in oocytes. The regulation of NCC trafficking by WNKs involves a 
sequential inhibitory cascade, in which KS-WNK1 inhibits WNK1, WNK1 inhibits WNK4 
[136], and WNK4 inhibits NCC [134]. The inhibition of NCC by WNK4 is not caused by 
endocytosis [35], but rather by promoting lysosomal degradation [112]. This inhibition is 
mediated by the ERK1/2 signaling pathway and the lysosomal targeting receptor sortilin [141, 
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142]. Interestingly, angiotensin II converts WNK4 from an inhibitor to an activator of NCC 
[101]. In contrast to WNK4, WNK3 stimulates NCC [97], but its actions are less well-defined. 
WNK3 and WNK4 not only have divergent effects on NCC, they also antagonize each other. 
Indeed, it appears to be the ratio between WNK3 and WNK4 that determines the net effect on 
NCC [135]. The phosphorylation of NCC is mediated by SPAK [79]; several WNKs interact 
with SPAK and therefore indirectly control the phoshorylation-step of NCC. Interactions 
between SPAK and WNK1 [79], WNK3 [34], and WNK4 [102] have been reported. However, 
the brain but not the kidney isoform of WNK3 can activate NCC and does so through a SPAK-
independent mechanism [34]. Two isoforms of SPAK have been identified, including full-length 
SPAK (FL-SPAK) and kidney-specific SPAK (KS-SPAK or SPAK2), of which the latter 
isoform has low expression levels in the DCT [73]. KS-SPAK, which lacks the kinase domain, 
inhibits FL-SPAK and OSR1, which are both known to phosphorylate NKCC2. This may 
explain why in mice the knockout of SPAK results in decreased NCC phosphorylation (absence 
of full-length SPAK), but increased NKCC2 phosphorylation (no inhibition of FL-SPAK or 
OSR1 by KS-SPAK) [36, 73].  
SPAK deficiency, however, does not completely inhibit NCC phosphorylation [73, 139], 
suggesting the involvement of other kinases or phosphatases. Both SPAK isoforms are also 
involved in the stimulatory effect of vasopressin on NCC and NKCC2 [83, 91]. Namely, 
vasopressin stimulates FL-SPAK in the DCT to phosphorylate NCC, whereas it attenuates KS-
SPAK to allow FL-SPAK and OSR1 to phosphorylate NKCC2 [104]. Although SGK1 was first 
recognized as an activator of ENaC [127], later reports also showed effects on NCC [115]. SGK1 
and NCC do not seem to interact directly, but rather through WNK4 and Nedd4-2 [2, 98]. SGK1 
phosphorylates WNK4 and this phosphorylation step reduces the inhibition of WNK4 on NCC 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
11 
 
[98, 100]. Because SGK1 is sensitive to aldosterone, this pathway appears to be involved in the 
activation of NCC by aldosterone [100]. The opposite is also true, because SGK1 knockout mice 
failed to increase NCC activity during a low sodium diet [115].  
 
Ubiquitin ligases 
Recent data indicate that Nedd4-2 is yet another player in the pathway by which aldosterone 
activates NCC (Figure 3) [2, 99]. Nedd4-2 was shown to stimulate ubiquitylation of NCC and 
decreased its activity and surface expression in vitro and in vivo, while SGK1 prevented these 
effects [2]. The pathophysiological significance of the regulation of NCC by Nedd4-2 was shown 
by the generation of inducible nephron-specific Nedd4-2 knockout mice [99]. These mice 
exhibited salt-dependent hypertension that was characterized by upregulation of total and 
phosphorylated NCC and sensitivity to thiazides. The deletion of Nedd4-2 also affected ENaC 
and ROMK, which were down- and upregulated, respectively. This may explain the additional 
characteristics of these mice, namely that they had a normal Na
+
/K
+
 balance and were not 
hyperkalemic. Similar to Nedd4-2, Kelch-like 3 and Cullin 3 are also involved in ubiquitylation, 
because they are components of an E3 ubiquitin ligase complex. Although mutations in Kelch-
like 3 and Cullin-3 cause hyperkalemic hypertension that is reversible with thiazides, these 
proteins probably do not interact directly with NCC. Instead, Kelch-like 3 binds and 
ubiquitinates WNK4 and the subsequent degradation of WNK4 would be expected to increase 
NCC activity (Figure 3) [89, 106, 128, 132].  
 
Other signaling molecules 
Although the network reviewed above is largely interconnected (Figure 3), additional NCC 
regulatory pathways exist. One example is the regulation of NCC by phorbol esters [54]. This 
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effect is mediated through Ras guanyl-releasing protein 1 and ERK1/2, which stimulates 
ubiquitylation and endocytosis of NCC [55]. Furthermore, NCC phosphorylation is not only 
controlled by kinases but also by phosphatases including phosphatase 4 [33]. Finally, the process 
that controls the phosphorylation of NCC may also cause less ubiquitylation, thereby increasing 
the number of cotransporters available for phosphorylation [51].   
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Relation to human disease  
Gitelman syndrome 
The clearest demonstration of the functional relevance of NCC comes from human monogenetic 
diseases that affect NCC function (Table 2). Inactivating mutations in SLC12A3 cause the so-
called Gitelman syndrome [107]. Gitelman syndrome is an autosomal recessive disorder that is 
characterized by hypokalemia, hypomagnesemia, metabolic alkalosis, hypocalciuria, and low to 
normal arterial blood pressure. Missense mutations account for approximately 59% of the 
mutations in Gitelman syndrome and compound heterozygosity is common [113, 123]. Gender 
and the type of mutation contribute to phenotypic variability, with males and patients with 
homozygous deep intronic mutations exhibiting a more severe phenotype [64, 65]. Novel 
mutations are still being identified in Gitelman syndrome and these genetic defects lead to 
impaired production, processing, insertion or regulation of the NCC protein (type I, II, III or IV 
mutations) [32, 113, 123]. Although Gitelman syndrome is usually a relatively benign disorder 
that often remains subclinical for many years, a recent report suggests that the electrolyte 
disorders associated with Gitelman syndrome may result in chronic kidney disease and glucose 
intolerance [113]. On the other hand, heterozygous mutations in NCC may prevent hypertension 
and cardiovascular diseases [52] and improve bone-density [17] likely because they induce mild 
sodium excretion and a positive calcium balance. NCC knockout mice recapitulate the phenotype 
of Gitelman syndrome, although some features become manifest only when the animals are 
challenged [73, 80, 105, 139]. In line with the current model of NCC regulation (Figure 3), 
genetically modified mice with overexpression of WNK4, deficiency in SPAK or its kinase 
domain, also exhibit features of Gitelman syndrome [61, 88, 94, 139], although such mutations 
have not been identified in humans. Gitelman syndrome should be differentiated from the more 
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severe Bartter syndrome, which results from mutations affecting NKCC2, and is characterized by 
earlier onset of symptoms and hypercalciuria instead of hypocalciuria [47]. An intermediary 
phenotype is caused by mutations in CLCNKB which encodes a basolateral chloride channel that 
is expressed in both the thick ascending limb and the DCT (Table 2) [58]. Disturbed 
basolateral chloride efflux will indirectly impair apical NaCl transport through NKCC2 
and NCC.   
 
Familial hyperkalemic hypertension 
Familial hyperkalemic hypertension (FHHt) is the “mirror image” of Gitelman syndrome 
because, in addition to hyperkalemia and hypertension, it is characterized by hypercalciuria and 
metabolic acidosis [37]. Surprisingly, no activating mutations in SLC12A3 have been reported. 
Overexpression of NCC in transgenic mice also failed to induce hyperkalemic hypertension, but 
this may have been due to the fact that phosphorylated NCC was not increased [74]. Similarly, 
increasing NCC activity by inactivating KS-WNK1 was also not sufficient to cause 
hyperkalemic hypertension, because it was associated with a compensatory decrease in ENaC 
[38]. Instead, familial hyperkalemic hypertension is caused by mutations in the genes encoding 
WNK1, WNK4, Kelch-like 3 or Cullin-3, which result in overactivity of NCC (Table 2) [7, 68, 
131]. Because the WNKs regulate other transporters than NCC alone, these effects may also 
contribute to the FHHt-phenotype [37]. Intronic deletions in the WNK1 gene cause 
overexpression of WNK1 and therefore more inhibition of WNK4. The inhibition of WNK4 will 
relieve the inhibition of SPAK and will activate NCC (Figure 3). Similarly, missense mutations 
in the WNK4 gene give rise to a mutant protein that no longer inhibits SPAK resulting in NCC 
activation. Mutations in KLHL3 can be dominant or recessive and homozygous or heterozygous, 
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while the identified mutations in CUL3 were dominant, heterozygous and often de novo [7]. 
Mutations in KLHL3 and CUL3 seem to abrogate ubiquitylation of targets normally bound by 
KLHL3 including WNK4 [106]. Of the different mutations causing FHHt, CUL3 mutations have 
the most severe phenotype, including the youngest onset of hypertension and the highest serum 
potassium [7]. Another illustration that NCC activation is the final common pathway of the 
FHHt mutations is the fact that these disorders are all exquisitely sensitive to treatment with 
thiazide-type diuretics [71]. 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
16 
 
Drugs influencing NCC activity  
Drugs inhibiting NCC 
Several commonly used drugs inhibit or stimulate NCC activity (Table 1). The sensitivity of 
NCC for thiazide diuretics is well known and characterizes this cotransporter. Thiazides, 
however, do not exclusively inhibit NCC, but also the sodium-dependent bicarbonate-chloride 
cotransporter in the cortical collecting duct [63]. Thiazide diuretics were incidentally discovered 
while searching for better carbonic anhydrase inhibitors [86]. They were implemented clinically 
in 1958, long before it became apparent that their primary target is NCC [81]. Thiazide diuretics 
are the logical drug of choice for diseases with NCC overactivity such as the rare disorder FHHt. 
However, the clinical indication for thiazide diuretics is much broader. In fact, thiazide diuretics 
are still among the most commonly used drugs to treat hypertension worldwide. Although the 
natriuretic effect of these drugs undoubtedly contributes to their antihypertensive effect, this 
response also seems to be translated to an effect on vascular tone [9-11]. In addition, thiazides 
may directly cause vasodilation possibly through vascular potassium channel activation [92]. In 
addition to hypertension, thiazide diuretics can also be used for sodium-retaining disorders such 
as heart failure, liver cirrhosis, nephrotic syndrome, and chronic kidney disease [8]. Because 
thiazide diuretics act in the tubular lumen, their action requires successful delivery to the DCT. 
This is mediated by active secretion of thiazide diuretics in the proximal tubule through organic 
anion transporter and multidrug resistance-associated protein 4 [39, 114]. This explains why a 
reduction in glomerular filtration rate results in reduced efficacy of thiazide diuretics. Patients 
with Gitelman syndrome also demonstrate a dramatically impaired natriuretic response to 
thiazides, a feature that may be used diagnostically [15]. The side-effect profile of thiazide 
diuretics resembles Gitelman syndrome with the exception of hyponatremia, which is only seen 
with thiazides [22, 24, 48].  
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Drugs stimulating NCC 
Drugs stimulating NCC activity have also been identified recently and they include the 
calcineurin inhibitors cyclosporine and tacrolimus (Table 1) [44, 76]. Calcineurin inhibitors are 
potent immunosuppressive drugs that are used clinically to prevent rejection after transplantation 
and sometimes in autoimmune disorders. Although cyclosporine and tacrolimus have different 
intracellular binding proteins, they both activate NCC, and this effect therefore appears to be a 
class effect [45]. Again, cyclosporine and tacrolimus do not seem to activate NCC directly, but 
influence the WNKs [76]. This possibility was already suggested by the side-effect profile of 
these drugs, which is similar to the phenotype of FHHt. Of interest, calcineurin is a protein 
phosphatase and protein phosphatases were recently shown to regulate NCC [33]. We were able 
to illustrate the clinical relevance of NCC activation by tacrolimus by linking it to hypertension 
[44]. That is, tacrolimus failed to induce hypertension in NCC knockout mice, whereas it caused 
more severe hypertension in NCC transgenic mice. Furthermore, a thiazide diuretic caused a 
larger urinary chloride excretion in patients on tacrolimus than in healthy volunteers or patients 
on sirolimus (a different immunosuppressant). This enhanced chloriuretic response to a thiazide 
was interpreted as an indication of increased transporter activity [15]. Also, the expression of 
total and phosphorylated NCC was increased in the kidney biopsies of patients treated with 
tacrolimus. Of interest, a model of cyclosporine nephrotoxicity showed the opposite effect on 
NCC, but this was attributed to inactivation of the renin-angiotensin system [62]. Furosemide, 
which blocks sodium transport in the thick ascending limb but not in the DCT, also increases 
NCC abundance. This effect is likely caused by the loop-diuretic induced enhanced sodium 
delivery to the DCT and the activation of the renin-angiotensin system [1]. The up-regulation of 
NCC likely compensates for the furosemide effect and hence may contribute to the phenomenon 
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of loop-diuretic resistance which frequently develops during chronic treatment. As such it 
provides the rationale for the combination of a loop-diuretic with a thiazide to overcome diuretic 
resistance [8]. Furthermore, recent studies in rats suggested that the cytostatic drug cisplatinum 
decreases renal NCC abundance. However, this effect is likely attributed to a general toxic effect 
on DCT cells, because also the expression of other DCT-specific proteins such as the magnesium 
channel TRPM6 and the calcium- and magnesium-binding protein parvalbumin were decreased 
[116].      
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Perspectives 
In this review we have highlighted several exciting new roles of NCC in sodium, potassium, and 
blood pressure regulation. These new insights have partly solved longstanding questions in 
physiology, but at the same time raise new questions. For example, although the model of NCC 
regulation is gaining more clarity (Figure 3), some of the interactions are still not well 
understood or even controversial. For example, WNK4 seems to be a negative regulator of NCC 
under some conditions, but may become a positive regulator in others [72]. The inhibition of 
NCC by dietary potassium may be mediated by WNK4 [87, 110, 120], but leaves the question 
open through which signal DCT cells “sense” dietary potassium. Pathophysiologically, the role 
of NCC in “essential” hypertension will likely remain a focus of future studies. The recent 
linkage of Cullin-3 and Kelch-like 3 to FHHt begs the question whether polymorphisms in these 
genes exist and whether they may contribute to human hypertension. The discovery that 
calcineurin inhibitors stimulate NCC to cause hypertension warrants a clinical study to evaluate 
whether thiazide diuretics are effective drugs to treat this side effect [44-46]. Especially for 
translational studies it will be important to have a measure of NCC activity in vivo. In addition to 
testing the response to a thiazide diuretic [15], the analysis of NCC in so-called urinary 
exosomes holds promise [43]. Urinary exosomes are vesicles derived from renal tubular 
epithelial cells that are thought to reflect the metabolic profile of these cells [93]. We recently 
showed that the abundance of phosphorylated NCC in urinary exosomes correlated with elevated 
aldosterone levels in animals and humans [117]. Although this review focused on NCC, sodium 
excretion by the kidney depends on many other sodium transporters, including NHE3, NKCC2, 
ENaC, and pendrin. Stimuli that activate NCC, sometimes also activate these other transporters, 
but an opposite, compensatory response may also occur [38, 84, 99]. In conclusion, the role of 
NCC in normal physiology and in the pathophysiology of hypertension is expanding and will 
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likely continue to do so in coming years. To fully grasp the potential of these insights for the 
treatment of human disease will likely require a more complete understanding of the molecular 
physiology of this fascinating cotransporter.  
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Table 1: Hormones, metabolic stimuli and drugs influencing NCC activity 
 Stimulus Effect References 
Hormones Angiotensin II Stimulatory [118] 
 Aldosterone Stimulatory¶ [53] 
 Glucocorticoids Stimulatory [124] 
 Vasopressin Stimulatory [83, 91, 104] 
 Insulin Stimulatory [13, 57, 108, 
109] 
 Estrogen Stimulatory [125] 
 Norepinephrine Stimulatory [82] 
Metabolic stimuli Dietary potassium Inhibitory [110, 120] 
 Dietary sodium* Inhibitory [14, 103] 
 Dietary magnesium* Stimulatory [25] 
 Acidosis* Stimulatory [26] 
Drugs Thiazide diuretics Inhibitory [16, 23] 
 Furosemide* Stimulatory [1] 
 Tacrolimus Stimulatory [44] 
 Cyclosporine† Stimulatory [76] 
 Cisplatin Inhibitory [116] 
 
Footnote: ¶ When high dietary K increases aldosterone, NCC may be inhibited; * Some of 
these effects may be mediated through aldosterone; † In a model of cyclosporine nephrotoxicity, 
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NCC was downregulated, but this may be attributed to kidney failure and reduced renin-
angiotensin activity [76]. 
Table 2: Characteristics of mutations causing Gitelman syndrome or familial hyperkalemic 
hypertension 
 
Disease Gene OMIM 
gene 
Human 
chromosome 
location 
Encoding 
protein 
Major phenotype Selected 
references 
Gitelman  
(OMIM 
263800) 
SLC12A3  600968 16q13 NCC Hypokalemic 
hypotension 
[107] 
 CLCNKB 602023 1p36.13  CLCNKB Variable [58] 
FHHt* 
(OMIM 
179820)  
WNK1 605232 12p13 WNK1 Hyperkalemic 
hypertension 
[131] 
 WNK4 601844 17q21 WNK4 Hyperkalemic 
hypertension 
[131] 
 KLHL3 605775 5q31 Kelch-
like 3 
Hyperkalemic 
hypertension 
[7] 
 CUL-3 603136 2q36 Cullin-3 Hyperkalemic 
hypertension 
[7, 68] 
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Abbreviation: * FHHt, familial hyperkalemic hypertension; OMIM, online Mendelian 
inheritance in man.  
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Figure legends 
 
Figure 1: Model of transcellular transport in the early distal convoluted tubule (DCT). A kidney 
tubule is shown schematically on the left indicating the locations of DCT type 1 and type 2 
(DCT1, DCT2) and the connecting tubule (CNT). The sodium chloride cotransporter (NCC) is 
primarily expressed in DCT1. A model of transcellular transport in DCT1 is shown on the right, 
including the apical transporters NCC and transient receptor potential channels TRPV5 (a 
calcium channel) and TRPM6 (a magnesium channel). On the basolateral side the sodium 
potassium ATPase pump is shown as well as the chloride channel ClC-Kb and the sodium-
calcium channel NCX1. This figure was adapted from [5, 59].  
 
Figure 2: Putative structure of the sodium chloride cotransporter. The twelve transmembrane 
domains are shown including the hydrophilic loop with the two glycosylation sites. A detailed 
image of the N-terminus is provided on the left showing the binding sites of γ-adducin and the 
kinases SPAK/OSR1. This figure was reproduced and adapted from [19] with kind permission. 
 
Figure 3: Current model of sodium chloride cotransporter regulation by kinases and 
ubiquitinases. The various interactions of the NCC regulatory pathway are shown as arrows 
(stimulatory) or as lines ending with perpendicular lines (inhibitory). Phosphorylation is 
indicated with the symbol “P”, whereas ubiquitylation is shown as “U”. SPAK/OSR1, WNK4, 
kidney-specific WNK1 (KS-WNK1) and long WNK1 (L-WNK1, also called WNK1) are 
kinases. The role of mutant WNK4 in familial hyperkalemic hypertension (FHHt) is also shown, 
which overrides the inhibitory effect of wild-type WNK4 on SPAK/OSR1. Nedd4-2 is a 
ubiquitinase, while Cullin-3 and Kelch-like 3 interact in a ubiquitylation complex that likely 
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ubiquitinates WNK4. Although WNK3 has been shown to interact with WNK4 and SPAK 
[90, 135], its precise role in NCC regulation remains less clear and we therefore decided not 
to include it. See text for further details. 
  
Figure 4: Inhibition of the sodium chloride cotransporter by dietary potassium (“high K”). The 
results of our recent studies on the inhibitory effect of dietary potassium on NCC are shown 
[110, 121]. Panel A shows that dietary potassium acutely downregulates phosphorylated NCC 
but not total NCC. Conversely, panel B shows that a chronic high potassium diet primarily 
decreased total NCC, but phosphorylated NCC less so. The high potassium diet was 2% and 
5%, respectively, and the low sodium diet was < 0.001% [110, 121].    
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